^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600_K601delinsE

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    7ms
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion • BRAF V600R • BRAF V600D • BRAF V600M • BRAF T599 • BRAF V600_K601delinsE • BRAF K601
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    1year
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF V600E • BRAF mutation • BRAF V600K • BRAF fusion • BRAF V600R • BRAF V600D • BRAF V600M • BRAF T599 • BRAF V600_K601delinsE • BRAF K601
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    almost2years
    A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    2years
    A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=38 --> 17
    Enrollment closed • Enrollment change • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF fusion • BRAF K601E • BRAF G469A • BRAF L597Q • BRAF L485W • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    2years
    Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience. (PubMed, Melanoma Res)
    Four patients received combined BRAF/MEK inhibitors, two patients BRAF inhibitor monotherapy, and six patients were treated with ICI for advanced melanoma; four patients received adjuvant treatment with nivolumab. Given the few cases and the absence of randomized clinical trials, it is important to report clinical experiences, which can guide physicians in the treatment of melanomas harboring rare BRAF mutations.
    Clinical • Journal • PD(L)-1 Biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600K • BRAF K601E • BRAF V600R • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597
    |
    Opdivo (nivolumab)
    3years
    Treatment outcomes of patients with cutaneous melanoma harbouring rare BRAF mutations (NCRI 2021)
    Conclusion Our results - on a small number of patients - suggest that patients with rare BRAF mutations may have inferior survival outcomes with first line targeted treatment, compared with patients with classical BRAF mutations. Impact statement Our findings add to the limited clinical knowledge on rare BRAF mutations in melanoma and may help guide treatment decisions on this small subset of patients.
    Clinical • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF mutation • BRAF V600K • BRAF K601E • BRAF D594G • BRAF V600R • BRAF D594N • BRAF L597S • BRAF T599 • BRAF V600_K601delinsE • BRAF K601 • BRAF L597
    3years
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Recruiting, University Health Network, Toronto | Trial completion date: Sep 2021 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF V600E • BRAF mutation • BRAF V600K • BRAF fusion • BRAF V600R • BRAF V600D • BRAF V600M • BRAF T599 • BRAF V600_K601delinsE • BRAF K601
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    almost4years
    Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series. (PubMed, Diagn Pathol)
    Our cases provide evidence for utility of NGS in facilitating diagnosis and treatment decisions.
    Clinical • Journal • Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR L861Q • BRAF K601E • EGFR G719A • EGFR G719S • EGFR G719S + EGFR L861Q • BRAF V600_K601delinsE • BRAF K601
    |
    Conmana (icotinib)
    over4years
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Recruiting, University Health Network, Toronto | Active, not recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF V600E • BRAF mutation • BRAF V600K • BRAF fusion • BRAF V600R • BRAF V600D • BRAF V600M • BRAF T599 • BRAF V600_K601delinsE • BRAF K601
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    over4years
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting
    Enrollment closed • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF V600E • BRAF mutation • BRAF V600K • BRAF fusion • BRAF V600R • BRAF V600D • BRAF V600M • BRAF T599 • BRAF V600_K601delinsE • BRAF K601
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)